Lutein-Loaded Solid Lipid Nanoparticles for Ocular Delivery: Statistical Optimization and Ex Vivo Evaluation

Shah, Sunny; Bhanderi, Brijesh; Soniwala, Moinuddin; Chavda, Jayant

doi:10.1007/s12247-021-09537-6

Cited by 13 publications

(7 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The preparation of emulsions includes the low-energy method [ 12 , 24 ], solvent evaporation method [ 25 ], ultrasonic method [ 26 ], electrostatic complexation [ 27 ], high pressure homogenization method [ 28 , 29 ] and others. The emulsions in this study were prepared by a low-energy method.…”

Section: Methodsmentioning

confidence: 99%

Enhancing the stability of lutein emulsions with a water-soluble antioxidant and a oil-soluble antioxidant

Wang¹,

Zhang²,

Yan³

et al. 2023

Heliyon

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Enhancing the stability of lutein emulsions with a water-soluble antioxidant and a oil-soluble antioxidant

Wang¹,

Zhang²,

Yan³

et al. 2023

Heliyon

View full text Add to dashboard Cite

“…The amount of drug permeating through the corneal epithelium was plotted versus time. The apparent corneal permeability coefficient (cm/h) was determined according to the equation Kp = J ss /C 0 , where J ss (steady stat flux) was the slope of the linear portion (μg/h·cm 2 ) and C 0 was the initial drug concentration (μg/cm 2 ) [ 20 ].…”

Section: Methodsmentioning

confidence: 99%

Sertaconazole-Nitrate-Loaded Leciplex for Treating Keratomycosis: Optimization Using D-Optimal Design and In Vitro, Ex Vivo, and In Vivo Studies

et al. 2022

View full text Add to dashboard Cite

This study aims to develop efficient topical therapy for keratomycosis using sertaconazolenitrate (STZN)-loaded leciplex (LP). The D-optimal design was used to optimize STZN-loaded LP by utilizing soy phosphatidylcholine (SPC) molar ratio (X1), cationic surfactant molar ratio (X2), and cationic surfactant type (X3) as the independent variables, whereas their impact was studied for entrapment efficiency percent (EE; Y1), particle size (PS; Y2), polydispersity index (PDI; Y3), zeta potential (ZP; Y4), and permeability coefficient (Kp; Y5). The optimized formula was evaluated regarding morphology, ex vivo permeation, mucoadhesion, stability, and in vivo studies. The optimized formula was spherical and showed EE of 84.87 ± 1.71%, PS of 39.70 ± 1.35 nm, PDI of 0.242 ± 0.006, ZP of +54.60 ± 0.24 mV, and Kp of 0.0577 ± 0.0001 cm/h. The ex vivo permeation study revealed that the optimized formula enhanced the Kp and corneal deposition by 2.78 and 12.49 folds, respectively, compared to the aqueous drug dispersion. Furthermore, the optimized formula was stable and revealed promising mucoadhesion properties. Finally, the in vivo studies showed that the optimized formula was superior to the drug dispersion in treating rats with induced keratomycosis. These results confirmed the capabilities of LP as a promising nanocarrier for treating ocular diseases topically.

show abstract

“…Early research on curcumin SLNs with PEGylated SLNs indicated positive outcomes in macular degeneration [ 172 ]. Shah et al developed and optimized lutein-loaded SLNs for the treatment of AMD [ 173 ]. The ex vivo evaluation revealed that the optimized formulation did not cause any damage to the cornea and sustained the drug release for up to 8 h in simulated tear fluid [ 173 ].…”

Section: Nanocarrier Systems In the Delivery Of Neuroprotective Agentsmentioning

confidence: 99%

“…Shah et al developed and optimized lutein-loaded SLNs for the treatment of AMD [ 173 ]. The ex vivo evaluation revealed that the optimized formulation did not cause any damage to the cornea and sustained the drug release for up to 8 h in simulated tear fluid [ 173 ]. In a different study, Noha et al formulated brimonidine NLCs and SLNs.…”

Section: Nanocarrier Systems In the Delivery Of Neuroprotective Agentsmentioning

confidence: 99%

Nanocarriers for the Delivery of Neuroprotective Agents in the Treatment of Ocular Neurodegenerative Diseases

et al. 2023

View full text Add to dashboard Cite

Retinal neurodegeneration is considered an early event in the pathogenesis of several ocular diseases, such as diabetic retinopathy, age-related macular degeneration, and glaucoma. At present, there is no definitive treatment to prevent the progression or reversal of vision loss caused by photoreceptor degeneration and the death of retinal ganglion cells. Neuroprotective approaches are being developed to increase the life expectancy of neurons by maintaining their shape/function and thus prevent the loss of vision and blindness. A successful neuroprotective approach could prolong patients’ vision functioning and quality of life. Conventional pharmaceutical technologies have been investigated for delivering ocular medications; however, the distinctive structural characteristics of the eye and the physiological ocular barriers restrict the efficient delivery of drugs. Recent developments in bio-adhesive in situ gelling systems and nanotechnology-based targeted/sustained drug delivery systems are receiving a lot of attention. This review summarizes the putative mechanism, pharmacokinetics, and mode of administration of neuroprotective drugs used to treat ocular disorders. Additionally, this review focuses on cutting-edge nanocarriers that demonstrated promising results in treating ocular neurodegenerative diseases.

show abstract

Lutein-Loaded Solid Lipid Nanoparticles for Ocular Delivery: Statistical Optimization and Ex Vivo Evaluation

Cited by 13 publications

References 68 publications

Enhancing the stability of lutein emulsions with a water-soluble antioxidant and a oil-soluble antioxidant

Enhancing the stability of lutein emulsions with a water-soluble antioxidant and a oil-soluble antioxidant

Sertaconazole-Nitrate-Loaded Leciplex for Treating Keratomycosis: Optimization Using D-Optimal Design and In Vitro, Ex Vivo, and In Vivo Studies

Nanocarriers for the Delivery of Neuroprotective Agents in the Treatment of Ocular Neurodegenerative Diseases

Contact Info

Product

Resources

About